CID-078 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must not have had certain cancer treatments or surgeries within specific time frames before starting the trial.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, including various cancers like breast and lung cancer. Participants should have a tumor that's progressed after treatment or has no satisfactory alternative treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CID-078 in 21-day treatment cycles during Dose Escalation and Dose Expansion phases
End of Treatment
End of Treatment visit conducted within 7 days of the last dose or decision to withdraw
Safety Follow-up
Participants are monitored for safety 28 days after the End of Treatment visit
What Are the Treatments Tested in This Trial?
Interventions
- CID-078
Find a Clinic Near You
Who Is Running the Clinical Trial?
Circle Pharma
Lead Sponsor